雄激素受体-话题@MedSci

#雄激素受体#

81篇内容 | 3489人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1350574, encodeId=b33613505e44c, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Clin Cancer Res：转移性去势抵抗性前列腺癌c-MET和雄激素受体双重阻断:恩扎鲁胺和克唑替尼联合应用的一期研究, objectType=article, longId=201364, objectId=cf922013647f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf922013647f, replyNumber=0, likeNumber=157, createdTime=2020-09-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf922013647f, moduleTitle=Clin Cancer Res：转移性去势抵抗性前列腺癌c-MET和雄激素受体双重阻断:恩扎鲁胺和克唑替尼联合应用的一期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf922013647f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350573, encodeId=6b6d13505e39d, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Communications Biology：晚期前列腺癌帐长非编码RNAs与雄激素受体剪接因子相关 , objectType=article, longId=199159, objectId=d98c19915921, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d98c19915921, replyNumber=0, likeNumber=99, createdTime=2020-08-12, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d98c19915921, moduleTitle=Communications Biology：晚期前列腺癌帐长非编码RNAs与雄激素受体剪接因子相关 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d98c19915921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350572, encodeId=306313505e22d, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Mol Cell :雄激素受体结构对前列腺癌的启示, objectType=article, longId=198262, objectId=6dc719826240, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dc719826240, replyNumber=0, likeNumber=115, createdTime=2020-07-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dc719826240, moduleTitle=Mol Cell :雄激素受体结构对前列腺癌的启示, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dc719826240)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350571, encodeId=ac4513505e1a1, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Eur Urol：转移前列腺癌中雄激素受体无细胞DNA和RNA分析 , objectType=article, longId=196037, objectId=09ab19603e3d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09ab19603e3d, replyNumber=0, likeNumber=78, createdTime=2020-06-19, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09ab19603e3d, moduleTitle=Eur Urol：转移前列腺癌中雄激素受体无细胞DNA和RNA分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09ab19603e3d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350570, encodeId=a29713505e046, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=J Peiodontol：睾丸素和雄激素受体在雌性大鼠牙周病进展中的作用, objectType=article, longId=195102, objectId=40dd195102f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40dd195102f4, replyNumber=0, likeNumber=80, createdTime=2020-06-02, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40dd195102f4, moduleTitle=J Peiodontol：睾丸素和雄激素受体在雌性大鼠牙周病进展中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40dd195102f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350569, encodeId=ef24135056932, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Prostate Cancer P D：去势抵抗性前列腺癌中雄激素受体丝氨酸81和丝氨酸213位点的磷酸化研究, objectType=article, longId=194434, objectId=ac2319443452, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac2319443452, replyNumber=0, likeNumber=95, createdTime=2020-05-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac2319443452, moduleTitle=Prostate Cancer P D：去势抵抗性前列腺癌中雄激素受体丝氨酸81和丝氨酸213位点的磷酸化研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac2319443452)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350568, encodeId=84711350568eb, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Biochem Pharmacol：前列腺癌中代谢稳定的二苯胺衍生物能够抑制雄激素受体和BET蛋白 , objectType=article, longId=192053, objectId=aa691920531f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa691920531f, replyNumber=0, likeNumber=89, createdTime=2020-04-13, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa691920531f, moduleTitle=Biochem Pharmacol：前列腺癌中代谢稳定的二苯胺衍生物能够抑制雄激素受体和BET蛋白 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa691920531f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350567, encodeId=849e135056e7b, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌, objectType=article, longId=191239, objectId=94ff191239b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94ff191239b4, replyNumber=0, likeNumber=105, createdTime=2020-04-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94ff191239b4, moduleTitle=拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94ff191239b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350566, encodeId=f6b41350566f8, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Sci Rep：雄激素受体和聚（ADP-核糖）糖水解酶抑制剂能够增加前列腺细胞中雄激素阻断的效果 , objectType=article, longId=190411, objectId=10ab1904113e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10ab1904113e, replyNumber=0, likeNumber=82, createdTime=2020-03-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10ab1904113e, moduleTitle=Sci Rep：雄激素受体和聚（ADP-核糖）糖水解酶抑制剂能够增加前列腺细胞中雄激素阻断的效果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10ab1904113e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350565, encodeId=4b7e1350565a3, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Prostate Cancer P D：转移去势抵抗性前列腺癌中雄激素受体状态和AR-null表型的基于免疫组化评估, objectType=article, longId=189491, objectId=50d918949101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50d918949101, replyNumber=0, likeNumber=84, createdTime=2020-03-08, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50d918949101, moduleTitle=Prostate Cancer P D：转移去势抵抗性前列腺癌中雄激素受体状态和AR-null表型的基于免疫组化评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50d918949101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350564, encodeId=e9fd135056404, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Oncogene：具有短聚谷氨酸尾巴的雄激素受体能够增强Wnt/β-连环蛋白介导的前列腺致瘤过程, objectType=article, longId=189352, objectId=d033189352cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d033189352cf, replyNumber=0, likeNumber=91, createdTime=2020-03-06, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d033189352cf, moduleTitle=Oncogene：具有短聚谷氨酸尾巴的雄激素受体能够增强Wnt/β-连环蛋白介导的前列腺致瘤过程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d033189352cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350563, encodeId=b4e81350563bd, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Nat Commun：前列腺癌中雄激素受体结合位点高度变异, objectType=article, longId=188536, objectId=5d7e18853640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d7e18853640, replyNumber=0, likeNumber=79, createdTime=2020-02-23, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d7e18853640, moduleTitle=Nat Commun：前列腺癌中雄激素受体结合位点高度变异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d7e18853640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350562, encodeId=a73b1350562eb, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=强生的雄激素受体拮抗剂Erleada，获得欧洲药品管理局批准治疗去势敏感型前列腺癌, objectType=article, longId=187284, objectId=4eb418e284e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eb418e284e5, replyNumber=0, likeNumber=113, createdTime=2020-02-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eb418e284e5, moduleTitle=强生的雄激素受体拮抗剂Erleada，获得欧洲药品管理局批准治疗去势敏感型前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eb418e284e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350561, encodeId=6d72135056149, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Oncogene：GRK2能够增强前列腺和前列腺肿瘤的雄激素受体依赖性, objectType=article, longId=187117, objectId=677818e11789, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=677818e11789, replyNumber=0, likeNumber=104, createdTime=2020-02-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=677818e11789, moduleTitle=Oncogene：GRK2能够增强前列腺和前列腺肿瘤的雄激素受体依赖性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=677818e11789)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350560, encodeId=262d135056040, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=口服雄激素受体抑制剂Nubeqa在III期前列腺癌研究中取得成功, objectType=article, longId=187116, objectId=145b18e11654, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=145b18e11654, replyNumber=0, likeNumber=112, createdTime=2020-02-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=145b18e11654, moduleTitle=口服雄激素受体抑制剂Nubeqa在III期前列腺癌研究中取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=145b18e11654)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350559, encodeId=72dd13505596a, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Oncogene：BCOR偶联H2A单泛素化来抑制雄激素受体靶标基因来调控前列腺癌增殖, objectType=article, longId=186645, objectId=102218664501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=102218664501, replyNumber=0, likeNumber=93, createdTime=2020-01-22, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=102218664501, moduleTitle=Oncogene：BCOR偶联H2A单泛素化来抑制雄激素受体靶标基因来调控前列腺癌增殖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=102218664501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350558, encodeId=3cd0135055819, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Nat Commun：LRIG1是前列腺癌中一个多效性的雄激素受体调控反馈肿瘤抑制因子, objectType=article, longId=185291, objectId=54801852915a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54801852915a, replyNumber=0, likeNumber=86, createdTime=2019-12-28, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54801852915a, moduleTitle=Nat Commun：LRIG1是前列腺癌中一个多效性的雄激素受体调控反馈肿瘤抑制因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54801852915a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350557, encodeId=3781135055ed6, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=西安杨森宣布旗下新一代雄激素受体抑制剂安森珂(R)在华上市, objectType=article, longId=183710, objectId=6798183e1036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6798183e1036, replyNumber=0, likeNumber=96, createdTime=2019-11-29, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6798183e1036, moduleTitle=西安杨森宣布旗下新一代雄激素受体抑制剂安森珂(R)在华上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6798183e1036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350556, encodeId=2fbe1350556d4, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=强生的雄激素受体抑制剂Erleada获得FDA批准，治疗转移性去势敏感性前列腺癌, objectType=article, longId=179672, objectId=33491e967221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33491e967221, replyNumber=0, likeNumber=103, createdTime=2019-09-20, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33491e967221, moduleTitle=强生的雄激素受体抑制剂Erleada获得FDA批准，治疗转移性去势敏感性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33491e967221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350555, encodeId=7ecb1350555b5, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, objectTitle=Oncogene：TXNDC9能够调控氧化应激诱导的雄激素受体信号来促进前列腺癌恶化, objectType=article, longId=179500, objectId=756b1e95004a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756b1e95004a, replyNumber=0, likeNumber=86, createdTime=2019-09-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756b1e95004a, moduleTitle=Oncogene：TXNDC9能够调控氧化应激诱导的雄激素受体信号来促进前列腺癌恶化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=756b1e95004a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

雄激素受体

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Clin Cancer Res：转移性去势抵抗性前列腺癌c-MET和雄激素受体双重阻断:恩扎鲁胺和克唑替尼联合应用的一期研究

2020-09-30

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Communications Biology：晚期前列腺癌帐长非编码RNAs与雄激素受体剪接因子相关

2020-08-12

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Mol Cell :雄激素受体结构对前列腺癌的启示

2020-07-30

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Eur Urol：转移前列腺癌中雄激素受体无细胞DNA和RNA分析

2020-06-19

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

J Peiodontol：睾丸素和雄激素受体在雌性大鼠牙周病进展中的作用

2020-06-02

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Prostate Cancer P D：去势抵抗性前列腺癌中雄激素受体丝氨酸81和丝氨酸213位点的磷酸化研究

2020-05-21

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Biochem Pharmacol：前列腺癌中代谢稳定的二苯胺衍生物能够抑制雄激素受体和BET蛋白

2020-04-13

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌

2020-04-03

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Sci Rep：雄激素受体和聚（ADP-核糖）糖水解酶抑制剂能够增加前列腺细胞中雄激素阻断的效果

2020-03-21

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Prostate Cancer P D：转移去势抵抗性前列腺癌中雄激素受体状态和AR-null表型的基于免疫组化评估

2020-03-08

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Oncogene：具有短聚谷氨酸尾巴的雄激素受体能够增强Wnt/β-连环蛋白介导的前列腺致瘤过程

2020-03-06

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Nat Commun：前列腺癌中雄激素受体结合位点高度变异

2020-02-23

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

强生的雄激素受体拮抗剂Erleada，获得欧洲药品管理局批准治疗去势敏感型前列腺癌

2020-02-04

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Oncogene：GRK2能够增强前列腺和前列腺肿瘤的雄激素受体依赖性

2020-02-03

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

口服雄激素受体抑制剂Nubeqa在III期前列腺癌研究中取得成功

2020-02-03

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Oncogene：BCOR偶联H2A单泛素化来抑制雄激素受体靶标基因来调控前列腺癌增殖

2020-01-22

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Nat Commun：LRIG1是前列腺癌中一个多效性的雄激素受体调控反馈肿瘤抑制因子

2019-12-28

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

西安杨森宣布旗下新一代雄激素受体抑制剂安森珂(R)在华上市

2019-11-29

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

强生的雄激素受体抑制剂Erleada获得FDA批准，治疗转移性去势敏感性前列腺癌

2019-09-20

zhaojie88 (审核中...)

前往app查看评论内容

#雄激素受体#

Oncogene：TXNDC9能够调控氧化应激诱导的雄激素受体信号来促进前列腺癌恶化

2019-09-17

科室
- - 订阅+
  - 更多科室
工具
服务